14x Revenue (average.metric for ASX listed pharma) or 45x Ebitda ..as per April 2023 EurozHart report..
go to Botanix website, under invest ..analyst coverage...
at usd 100mln sales , Mr. Market on average should value us at usd 1.4bln....but with our growth rates..like Japan 67% yoy and pipeline of super promising product we can be assured of Very conservatively usd2 bln valuation..
14x Revenue (average.metric for ASX listed pharma) or 45x Ebitda...
-
- There are more pages in this discussion • 2,554 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.055(16.9%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 38.0¢ | 33.0¢ | $7.103M | 19.63M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 134000 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 650314 | 19 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |